Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease.
Int J Pharm
; 600: 120461, 2021 May 01.
Article
in En
| MEDLINE
| ID: mdl-33711470
ABSTRACT
Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disorder of gastrointestinal tract with rising incidence. Established treatments of IBD are characterized by significantly adverse effects, insufficient therapeutic efficacy. Employing the oral nano-drug delivery systems for targeted therapy is capable of effectively avoiding systematic absorption and increasing local drug concentration, consequently leading to decreased adverse effects and improved therapeutic outcomes. This review gives a brief profile of pathophysiological considerations in terms of developing disease-directed drug delivery systems, then focuses on mechanisms and strategies of current oral nano-drug delivery systems, including size-, enzyme-, redox-, pH-, ligand-receptor-, mucus-dependent systems, and proposes the future directions of managements for IBD.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pharmaceutical Preparations
/
Inflammatory Bowel Diseases
/
Colitis
Limits:
Humans
Language:
En
Journal:
Int J Pharm
Year:
2021
Document type:
Article
Affiliation country: